Issuu on Google+

Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email!

Global Angiongenesis Inhibitors and Stimulators Industry Published on May 2012

Report Summary This report analyzes the worldwide markets for Angiogenesis Inhibitors and Stimulators in US$ Million by the following Product Segments: Angiogenesis Inhibitors, and Angiogenesis Stimulators. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 69 companies including many key and niche players such as Abbott Laboratories, Adnexus Therapeutics, Inc., Æterna Zentaris Inc., Amgen, Inc., Angstrom Pharmaceuticals Inc., AstraZeneca Plc, Bayer HealthCare AG, Callisto Pharmaceuticals, Inc., Celgene Corporation, Celltech Group Plc., Cephalon Inc., Eisai Inc., Eli Lilly And Company, ImClone Systems Inc., EntreMed Inc., GenVec Inc., Genzyme Corp., GlaxoSmithKline plc, Merck KGaA, Novartis, OSI Pharmaceuticals, Inc., Eyetech, Inc., Pfizer Inc., Progen Industries, Regeneron Pharmaceuticals, Roche, Genentech Inc., Chugai Pharmaceutical Co. Ltd., Silence Therapeutics, and ThromboGenics Limited. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Content

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers

I-1 I-2

Data Interpretation & Reporting Level

I-3

Quantitative Techniques & Analytics

I-3

Product Definitions and Scope of Study 1. Angiogenesis Inhibitors 2. Angiogenesis Stimulators

I-3 I-3 I-4

II. EXECUTIVE SUMMARY 1. MARKET OUTLOOK

II-1

Angiogenesis: In the Spotlight

II-1

Angiogenesis: A Preview

II-1

2. MARKET OVERVIEW

II-2

Angiogenesis Makes Inroads: A Retrospect

II-2

Angiogenesis: Ushering-In a New Era Angiogenesis: Fact File

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

II-2 II-3

Page 1/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Milestones in Research Achieved Over the Years

II-4

Anti-Angiogenic Drugs Market - An Overview

II-5

Angiogenic Inhibitors Market to Surge

II-5

The Long Journey for Anti-Angiogenesis Therapies

II-5

Approved Anti-Angiogenesis Drugs in the Market

II-6

Select FDA-Approved Anti-Angiogenic Drugs/ Therapeutics In Oncology By Type Monoclonal Antibody Therapies

II-6

Small Molecule Tyrosine Kinase Inhibitors

II-7

Inhibitors of mTOR

II-8

Other Anti-Angiogenic Agents

II-8

Leading Drugs in the Market

II-9

Avastin Leads the Fray

II-9

Table 1: Select Leading Drugs in the Global Anti-Angiogenesis Market: Annual Sales in US$ Million for Years 2008 & 2009 (includes corresponding Graph/Chart) Overview of Select Leading Drugs Avastin

II-10

Survival Benefit Conferred by Avastin

II-11

Mechanism of Action

II-12

General Mode of Delivery

II-12

Side Effects Elicited on Administering Avastin

II-12

ERBITUX' (Cetuximab)

II-12

Regulatory Approvals

II-13

Erbitux in Head and Neck Cancer

II-13

Glivec/Gleevec (imatinib mesylate)

II-14

Herceptin (Tractuzumab) Sutent (Sunitinib)

II-14 II-14

Other Regulatory Approvals

II-15

Sunitinib in Various Indications

II-15

Sunitinib in Renal Cell Carcinoma (RCC)

II-15

Sutent in Gastrointestinal Stromal Tumors (GIST) Cost Related Issues Tarceva (Erlotinib)

II-9

II-10

II-16

II-16 II-16

Other Regulatory Approvals

II-16

Thalomid速 (Thalidomide)

II-17

Table 2: Thalomid - Percentage Breakdown Based on Relative Oncology Application (includes corresponding Graph/Chart) Cilengitide Imiquimod

II-17

II-18 II-18

Angiogenesis Inhibitors - Pipeline Status

II-19

Select Anti-Angiogenesis Drugs in Phase III Development

II-19

Select Anti-Angiogenesis Drugs in Phase II Development

II-20

Select Anti-Angiogenesis Drugs in Phase I Development

II-21

Select Approved Indications of Anti-VEGF/VEGFR Drugs Novel Targets for Anti-Angiogenic Activity Select Approved HER Receptor-Targeting Drugs Select Approved m-TOR Inhibitors Integrins

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

II-21

II-22 II-22 II-22 II-23

Page 2/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Select Integrin Targeting Drugs under Development

II-23

Angiogenic Inhibitors - By Disease Application Cancer

II-23

II-23

Various Types of Cancers Targeted by Angiogenesis Inhibitors in Phase III Clinical Development

II-24

Diabetic Retinopathy

II-24

Female Reproductive Cycle Psoriasis

II-24 II-24

Inflammatory Diseases

II-25

Table 3: Classification of Anti-Angiogenic Compounds Based on Most Commonly Targeted Indication (includes corresponding Graph/Chart)

II-25

Angiogenesis Inhibitors in Eye Related Diseases

II-25

Age-Related Macular Degeneration

II-26

Wet AMD

II-26

Dry AMD

II-26

Select Anti-Angiogenic Drugs Approved by FDA for Treatment of Eye Diseases

II-27

Angiogenesis Inhibitors in Dermatology

II-27

Select Drugs/Therapeutics with Angiogenic Mode of Action Approved by FDA for Dermatology 3. MARKET TRENDS

II-27 II-28

Cancer - The Key Target Indication for Research in AntiAngiogeneis Drugs

II-28

Avastin Continues to Record Robust Growth

II-28

New Markets Offer Higher Potential for Herceptin

II-28

Increased Use Drives Tarceva's Growth in Developed Markets

II-28

Angiogenesis Inhibitors Continue to Dominate RCC Drug Market Votrient to Lead Renal Cell Carcinoma (RCC) Drug Market

II-29 II-29

Table 4: Leading Drugs in the Global Second Line Advanced Renal Cell Carcinoma Market (2010): Percentage Breakdown by Value Sales for Nexavar, Torisel, Afinitor, Avastin, and Others (includes corresponding Graph/Chart)

II-30

Clinical Benefits of Votrient Over Sutent

II-30

US FDA Revokes Avastin Approval for Breast Cancer

II-31

4. ANGIOGENESIS REPERTOIRE An In-depth Insight into Angiogenesis

II-32 II-32

Angiogenesis: At a Glance

II-32

Requisites for Angiogenesis

II-32

Endogenous Regulators of Angiogenesis

II-33

Angiogenic Process: Sequence of Events

II-33

Angiogenesis Process in Children Angiogenesis Process in Adults The Process of Angiogenesis in Thyroid Gland 5. ANGIOGENESIS INHIBITORS

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

II-34 II-34 II-34 II-35

Page 3/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Angiogenic Inhibitors: Basic Framework

II-35

Natural Inhibitors

II-35

Thrombospondin

II-35

Interferon

II-35

Cryptic Inhibitors

II-35

Other Natural Inhibitors

II-35

Natural Sources for Anti-Angiogenic Action

II-36

Potential Anti-Angiogenic Drugs of Natural Origin

II-36

Angiogenic Inhibitors: On the Verge of Attaining Superior Clinical Efficacy

II-36

Endogenous vs Synthetic Agents

II-36

Angiogenesis Inhibitors: Classification Based on Source of Origin

II-37

Anti-Angiogenic Molecules: Classification Based on Mode of Action II-37 Broad Overview of Anti-Angiogenic Therapies

II-37

Pre-Requisites for Any Drug to be an Angiogenic Inhibitor

II-38

Specific Therapeutic Strategies of Anti- Angiogenesis Agents Inhibiting Angiogenesis In Vivo

II-38

II-39

Antiangiogenic Tumor Therapy

II-39

Antivascular Therapy: Adding a New Dimension

II-39

MMPs - Exhibiting Dual Role

II-39

Angiogenesis Inhibitors Vs Standard Chemotherapy

II-40

Comparison Between Cytostatic Antiangiogenesis and Cytotoxic Chemotherapy

II-40

Proteoglycan Mixture: Therapeutic Powerhouse

II-41

Features of VascuStatin

II-41

Angiogenesis Inhibition Versus Cytotoxic Therapy

II-41

Relationship Between Copper and Angiogenesis

II-41

Anti-Angiogenesis Action of Pencillamine

II-42

Outline of Steps Involved in Drug Discovery for Angiogenesis Drug Delivery: Their Influence on Therapeutics

II-42

II-42

6. PROMOTERS OF ANGIOGENESIS/ ANGIOGENESIS STIMULATORS Angiogenesis Stimulators

II-44

II-44

Growth Factors

II-44

Angiogenic Stimulators in the Market

II-44

Stimulators Exhibiting Profound Influence on Angiogenesis Vascular Endothelial Growth Factor (VEGF)

II-44 II-44

VEGF and Their Influence on Diabetes and Diabetic Retinopathy II-45 Fibroblast Growth Factors (FGFs)

II-45

Basic Fibroblast Growth Factor (bFGF)

II-45

Placental Growth Factor (PlGF)

II-45

Recombinant a4 Fragment

II-46

Hepatocyte Growth Factor/ Scatter Factor (HGF/SF) Angiogenin

II-46

II-46

Platelet Derived Endothelial Cell Growth Factor

II-46

Applications of Angiogenic Stimulators vis-Ă -vis Disease Perspective

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

II-46

Page 4/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Cardiac Diseases

II-46

Wound Healing and Burns

II-46

Critical Limb Ischaemia

II-47

Status of Angiogenic Inducers

II-47

Angiogenic Therapies for Tissue Repair & Regeneration

II-47

Select Devices Supporting Therapeutic Angiogenesis Angiogenesis in Ischemic Heart

II-47 II-48

Factors Influencing Ischemic Angiogenesis

II-48

Angiogenesis and CAD

II-48

Angiogenesis in Wound Healing

II-49

Factors Stimulating Wound Angiogenesis

II-49

Factors Impairing Wound Angiogenesis

II-49

Angiogenic Therapy Vs. Conventional Therapy

II-49

Types of Angiogensesis

II-50

Excessive Angiogenesis

II-50

Insufficient Angiogenesis

II-50

Tumor Angiogenesis

II-50

Sequence of Actions

II-50

Angiogenesis and Tumor Progression

II-50

Oncogenes vis-à-vis Potential Pro-angiogenic Activities on Tumor Angiogenesis

II-51

Role of Angiogenesis in Skin Diseases

II-51

Select Drugs & Their Targeted Application

II-52

Analysis of Developmental Activities Between Decades

II-52

Role of Enzymes and Inflammatory Cells in Angiogenesis

II-53

Angiogenic Imbalance Augments Retinal Neovascularization Oncogenes & VE -cadherin - A Facilitating Role

II-53

II-53

7. PRODUCT APPROVALS AND LAUNCHES

II-54

FDA Withdraws Approval of AstraZeneca's NDA for IRESSA ( gefitinib) Tablets

II-54

Pfizer Obtains European Approval for SUTENT® to Treat Pancreatic NET

II-54

Novartis Obtains FDA Approval of New Indication for Afinitor

II-54

FDA Approves Herceptin for Treating Metastatic Adenocarcinoma Roche Introduces Avastin in China

II-55

II-55

Pfizer Japan Receives Clearance for Torisel in Japan

II-55

GSK Obtains European Commission's Conditional Marketing Approval for Votrient

II-56

FDA Approves Tarceva® for Maintenance Treatment of NSCLC FDA Approves GlaxoSmithKline's Votrient

II-56

II-56

European Commission Grants Clearance to Torisel for Mantle Cell Lymphoma

II-56

Genetech Receives FDA Approval for Avastin in Renal Cell Carcinoma

II-57

FDA Approves Bevacizumab as Second Line Treatment for Glioblastoma

II-57

Novartis Obtains FDA Approval of Afinitor for Treating Renal

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

Page 5/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Cell Cancer

II-58

8. PRODUCT APPROVALS AND LAUNCHES - A HISTORIC PERSPECTIVE BUILDER

II-59

FDA Grants Clearance for Gleevec in Treatment of Gastrointestinal Stromal Tumor

II-59

Celgene's Thalidomide Pharmion' Receives EC Clearance for Treating Multiple Myeloma

II-59

Genentech Obtains FDA Approval for Avastin in Breast Cancer

II-59

FDA Approves Nexavar for Treatment of Hepatocellular Carcinoma

II-60

Wyeth Receives EC Clearance for TORISEL in Advanced Renal Cell Carcinoma

II-60

OSI and Roche Announce Approval of Tarceva® in Japan

II-60

ImClone Obtains FDA Label Expansion for Erbitux®, as Third Line Therapy in mCRC

II-60

REVLIMID® Obtains Swissmedic Authorization in Switzerland

II-61

REVLIMID® Receives Marketing Approval in European Union Wyeth Obtains FDA Clearance for Marketing Torisel

II-61 II-61

Chugai Obtains Approval for Avastin in Japan

II-62

Pfizer Obtains FDA Approval for Sunitinib in Metastatic Renal Cell Carcinoma

II-62

FDA Approves Herceptin in HER2-Overexpressing Breast Cancer Treatment

II-62

Genentech Receives FDA Approval for Bevacizumab in Non-Small Cell Lung Cancer

II-63

Amgen Obtains FDA Approval for Vectibix Treating mCRC

II-63

FDA Grants Marketing Approval for Lucentis in Wet AMD

II-63

Celgene Obtains FDA Clearance for Revlimid in Multiple Myeloma

II-64

FDA Approves Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer

II-64

Celgene Obtains FDA's Accelerated Approval for THALOMID

II-65

Celgene Obtains sNDA Approval for THALOMID from FDA

II-65

ImClone Obtains FDA Clearance for Erbitux® in the treatment of SCCHN

II-65

Pfizer's Sutent Receives FDA Nod for Treatment of Gastrointestinal Stromal Tumor

II-66

Celgene Receives FDA's Subpart H Approval for Revlimid in Myelodysplastic Syndromes

II-66

US FDA Approves OSI's Tarceva® for Treating Pancreatic Carcinoma II-66 9. RECENT INDUSTRY ACTIVITY

II-68

Valeant to Take Over Eyetech Teva Acquires Cephalo

II-68 II-68

Genentech to Carry Out Additional Trial of Avastin in Her2negative mBC

II-68

Pfizer to Seek regulatory Clearance for Axitinib in Europe and US II-68 FDA to Withdraw Avastin's Approval for Breast Cancer

II-69

Eyetech Receives QTDP Grant To Develop Extended- Release Formulation of Macugen®

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

II-69

Page 6/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! sanofi-aventis and Regeneron to Continue VELOUR Trial as Planned II-69 EntreMed Enters into Financing Deal for ENMD-2076 Development

II-69

Chugai Pharmaceuticals Fulfills Condition for Avastin's Approval II-70 Gilead Sciences to Take Over CGI Pharma

II-70

Mersana Commences XMT-1107 Phase I Clinical Trial

II-70

Astellas Pharma Acquires OSI Pharmaceuticals

II-71

Roche to Conduct a Trial on Anti-Cancer Antibody TB-403

II-71

Mersana Therapeutics Inks License Agreement With Teva

II-71

Acceleron Publishes Pre-clinical Data Study on ACE-041

II-72

Antisense Raises Capital to Continue Phase III Trabedersen Trial II-72 GSK Receives Positive Opinions from EMEA for Two Cancer Medicines II-72 EMEA Issues Positive Opinion on GSK's Votrient

II-73

EMEA Issues Positive Opinion on GSK's Anti Cancer Drug Candidate, Tyverb

II-73

Abbott Enters into Licensing Agreement with Pierre Fabre

II-73

Arno Therapeutics Inks Global Licensing Agreement with OSU

II-73

BI Initiates Late Stage Clinical Trials for Two Oncology Drug Candidates

II-74

AnGes Obtains US FDA Approval for Phase III Trial of Collategene' II-74 Silence Therapeutics and Intradigm Merge

II-74

Mersana Launches First Phase of XMT-1107 Clinical Trial

II-75

ImClone Receives Complete Response Letter for Erbitux速 sBLA From FDA

II-75

Oxigene Releases Encouraging Data from OXi4503 Pre-clinical Studies

II-76

Potentia Enters into Licensing and Purchase Option Deal with Alcon

II-76

Quark Receives Additional Patents for RTP 801 Gene Targeting Compounds

II-77

Simcere Enters into Collaboration Deal with OSI Pharmaceuticals II-77 Pfizer Acquires Wyeth in Cash & Stock Merger

II-78

Gene Signal Releases Interim Results from Phase II Study on GS-101

II-78

Onco to Conduct Second Phase Trial of Fuso's OTS102

II-78

Green Cross Obtains US FDA Approval for Greenstatin Clinical Trial

II-79

OXiGENE Acquire Symphony ViDA

II-79

Roche Releases Positive Results from Phase III Trial of Lucentis II-79 Pfizer Halts Phase III Sutent Study for Colorectal Cancer

II-80

Morphotek Obtains FDA Clearance for MORAb-004 IND Application GlaxoSmithKline Files MAA for Pazopanib in EU Roche Acquires Genentech

II-80

II-80 II-80

Fuso Commences Phase II/III Clinical Trail for OTS102

II-81

10. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-82 EntreMed to Funnel Resources on ENMD-2076 Development

II-82

OmegaGenesis Enters Into Collaboration with Mayo Clinic for Angiogenesis Research

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

II-82

Page 7/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Eli Lilly Acquires ImClone Systems

II-82

EntreMed Demonstrates Antitumor Effects of ENMD-2076

II-83

EntreMed Collaborates with JSB for ENMD-2076 Business Development II-83 Circadian Technologies Limited Acquires Vegenics

II-83

Fuso and OTS to Initiate Phase II Trial for OTS102

II-83

EntreMed Releases Pre-Clinical Findings of ENMD-2076 in Multiple Myeloma

II-83

Merck Serono Inks Development and Licensing Agreement with Bionomics

II-84

Roche Inks Licensing Agreement with ThromboGenics and BioInvent for TB-403

II-84

Aida Initiates Pre-Clinical Development of New Anti-Cancer Drug II-85 Cyclacel Pharmaceuticals Releases Pre-Clinical Data of CYC116

II-85

Astellas and CoMentis Ink Agreement to Develop and Commercialize Beta- Secretase Inhibitors

II-86

Kringle Pharma's NK4 Receives Patent Approval in Japan

II-86

UCB Releases Phase II Results of CDP791 in NSCLC Treatment Celgene Takes Over Pharmion

II-87

II-87

REVLIMID速 Obtains Orphan Drug Designation in Japan

II-87

TRACON Commences Phase I Clinical Trial on TRC105 Ark Therapeutics to Acquire Lymphatix

II-87 II-88

Access Takes Over Somanta

II-88

Pfizer Takes Over CovX

II-88

Callisto Restructures Licensing Agreement with Genzyme for Atiprimod

II-89

EntreMed Receives FDA Approval for ENMD-2076 IND Application

II-89

EC Grants Orphan Medicinal Status to REVLIMID for Treatment of CLC

II-90

Bristol-Myers Squibb Snaps Up Adnexus Therapeutics

II-90

Morvus Takes Over Two Companies

II-90

Merck Inks Agreement with BMS and ImClone for Erbitux速 Development And Commercialization

II-91

FDA Issues a Safety Labeling Update for Bevacizumab Drug

II-91

Fuso Initiates Phase I Clinical Study for OST102 Angiogenesis Inhibitor

II-91

CRC to Support Bionomics in BN069 Development

II-92

Peregrine Secures Licensing Rights for B2GP1 Angiogenesis Inhibitor

II-92

AnGes's Angiogenesis-Stimulating Drug Meets Primary End-Point in Phase III Study

II-92

ImClone Annuls Development Agreement with UCB

II-92

ArQule Partners with Kyowa Hakko in Cancer Compound Samaritan Snaps Up Metastatin Pharmaceuticals

II-93 II-93

EU Approves '2 Million Grants for VASOPLUS Consortium MGH Cancer Center Reports Results of AZD2171 Phase II Trial

II-93 II-93

AVEO Inks Exclusive Licensing Agreement with Kirin for Novel Anti-Cancer Compound

II-94

Sangamo and Edwards Ink Angiogenesis Asset Purchase Agreement

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

II-94

Page 8/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Covalon Secures Perfusion's Gene Therapy Solutions

II-94

Vical Strengthens Angiogenesis and Poloxamers IPR Portfolio Biomira Takes Over ProIX Pharmaceuticals

II-95

II-95

FDA Gives Out Warning on Bevacizumab Drug

II-95

Athenagen Merges with Zapaq

II-95

Tigris Secures Global Licensing Rights to Develop and Commercialize New Cancer Therapies

II-96

Bayer Yakuhin Files Marketing Application for Nexavar in Japan

II-96

Athenagen Purchases Assets of Osprey Pharmaceutical

II-96

Amgen Acquires Abgenix

II-96

Genmab Enters Exclusive Licensing Agreement with Bionomics

II-97

OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals

II-97

FDA Changes Labeling of Iressa, Limiting Use to NSCLC

II-97

Schering AG and Novartis Signs a Agreement to Commercialize Angiogenesis Inhibitor, PTK787

II-98

Bausch & Lomb Signs an Option Agreement with PTC Therapeutics Bausch & Lomb Receives License from Cephalon, Inc

II-98

II-98

Pharmacopeia Signs a Licensing Agreement with Allergan

II-99

Xantos Biomedicine and Cryptome Enters into Licensing Agreement II-99 EntreMed Receives US Patent

II-99

11. FOCUS ON SELECT GLOBAL PLAYERS Abbott Laboratories (USA)

II-100 II-100

Adnexus Therapeutics, Inc. (USA)

II-100

Æterna Zentaris Inc. (Canada) Amgen, Inc. (USA)

II-100 II-101

Angstrom Pharmaceuticals Inc. (USA) AstraZeneca Plc. (UK)

II-101 II-102

Bayer HealthCare AG (Germany)

II-102

Callisto Pharmaceuticals, Inc. (USA)

II-103

Celgene Corporation (USA) Celltech Group Plc. (UK) Cephalon Inc. (USA) Eisai Inc. (USA)

II-104 II-104 II-104 II-105

Eli Lilly And Company (USA)

II-105

ImClone Systems Inc. (USA)

II-105

EntreMed Inc. (USA)

II-106

GenVec Inc. (USA)

II-107

Genzyme Corp. (USA)

II-107

GlaxoSmithKline Plc (UK)

II-107

Merck KGaA (Germany) Novartis (Switzerland)

II-108 II-108

OSI Pharmaceuticals, Inc. (USA) Eyetech, Inc. (USA) Pfizer Inc. (USA) Progen Industries (Australia) Regeneron Pharmaceuticals Roche (Switzerland)

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

II-109 II-110 II-110 II-111 II-111 II-112

Page 9/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Genentech Inc. (USA)

II-113

Chugai Pharmaceutical Co. Ltd. (Japan) Silence Therapeutics

II-114 II-115

ThromboGenics Limited (Ireland)

II-115

12. GLOBAL MARKET PERSPECTIVE

II-116

Table 5: World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Geographic Region/Country - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)

II-116

Table 6: World Historic Review for Angiogenesis Inhibitors & Stimulators by Geographic Region/Country - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

II-117

Table 7: World 15-Year Perspective for Angiogenesis Inhibitors & Stimulators by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

II-118

Table 8: World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors by Geographic Region/Country - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

II-119

Table 9: World Historic Review for Angiogenesis Inhibitors by Geographic Region / Country - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

II-120

Table 10: World 15-Year Perspective for Angiogenesis Inhibitors by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

II-121

Table 11: World Recent Past, Current & Future Analysis for Angiogenesis Stimulators by Geographic Region/Country - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

II-122

Table 12: World Historic Review for Angiogenesis Stimulators

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

Page 10/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! by Geographic Region / Country - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

II-123

Table 13: World 15-Year Perspective for Angiogenesis Stimulators by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

II-124

III. MARKET 1. THE UNITED STATES

III-1

A.Market Analysis

III-1

Angiogenic Inhibitors

III-1

List of FDA Approved Anti-Angiogenic Drugs

III-1

Pipeline Status By Disease

III-2

Anti-Angiogenesis Therapeutics In Phase III Development for Renal Cell Carcinoma: As of 2010

III-2

Anti-Angiogenesis Therapeutics In Phase III Development for Breast Cancer Treatment: As of 2010

III-3

Angiogenesis Stimulators

III-4

Historical Market Snapshots

III-4

Market Influencers

III-5

Types of Drug Approvals

III-5

New Drug Approval (NDA)

III-5

Orphan Drug Act

III-5

Benefits Derived on Successful Grant of Orphan Drug Status Angiogenesis Foundation

III-5

Key Role of the Foundation in Angiogenesis The Rising Concern Cancer

III-5 III-6

III-6

Cancer Statistics in US

III-6

A Picture of Colon Cancer in the US

III-6

Pancreatic Cancer Vital Statistics

III-5

III-6 III-7

Table 14: New Cancer Cases in the US By Affected Site: 2009

III-7

Table 15: New Cancer Cases in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart)

III-9

Table 16: New Cancer Cases in Females in US by Leading Site:2009 (includes corresponding Graph/Chart)

III-10

Table 17: Cancer Related Deaths in the US By Affected

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

Page 11/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Site:2009

III-11

Table 18: Cancer Related Deaths in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart)

III-13

Table 19: Cancer Related Deaths in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart) AMD and DME Incidence in the US Rheumatoid Arthritis: Another Emerging Threat Diabetic Retinopathy

III-14

III-14 III-15 III-15

Coronary Artery Disease (CAD)

III-15

Myocardial Infarction Statistics in the US

III-15

Peripheral Arterial Disease B.Market Analytics

III-15 III-16

Table 20: The US Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Product Segments-Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart)

III-16

Table 21: The US Historic Review for Angiogenesis Inhibitors & Stimulators by Product Segments- Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

III-17

Table 22: The US 15-Year Perspective for Angiogenesis Inhibitors & Stimulators by Product Segments - Percentage Breakdown of Dollar Sales for Angiogenesis Inhibitors & Stimulators for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart) 2. EUROPE A.Market Analysis

III-18 III-19 III-19

Angiogenesis Market - A Historic Perspective Cancer Trends

III-19 III-19

Table 23: Cancer Incidence in Europe by Site (2009) (includes corresponding Graph/Chart) B.Market Analytics

III-20 III-21

Table 24: European Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Product Segments-Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

III-21

Table 25: European Historic Review for Angiogenesis

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

Page 12/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Inhibitors & Stimulators by Product Segments- Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

III-22

Table 26: European 15-Year Perspective for Angiogenesis Inhibitors & Stimulators by Product Segments - Percentage Breakdown of Dollar Sales for Angiogenesis Inhibitors & Stimulators for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

III-23

3. REST OF WORLD

III-24

A.Market Analysis

III-24

Japanese Market

III-24

Quest for New Opportunities

III-24

B.Market Analytics

III-25

Table 27: Rest of World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Product Segments-Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

III-25

Table 28: Rest of World Historic Review for Angiogenesis Inhibitors & Stimulators by Product Segments- Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

III-26

Table 29: Rest of World 15-Year Perspective for Angiogenesis Inhibitors & Stimulators by Product Segments - Percentage Breakdown of Dollar Sales for Angiogenesis Inhibitors & Stimulators for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart)

III-27

IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 69 (including Divisions/Subsidiaries - 85) -----------------------------------------Region/Country

Players

-----------------------------------------The United States Canada

50 2

Japan

3

Europe

22

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

Page 13/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! France

2

Germany

5

The United Kingdom Italy

6 3

Rest of Europe

6

Asia-Pacific (Excluding Japan)

8

------------------------------------------

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

Page 14/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: ƒ ƒ

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information Please verify that the product information is correct and select the format(s) you require. Global Angiongenesis Inhibitors and Stimulators Industry

Product Formats Please select the product formats and the quantity you require.

1 User License--USD 4 950.00

Quantity: _____

Contact Information Please enter all the information below in BLOCK CAPITALS

Title:

Mr

Mrs

Dr

Miss

Ms

Prof

First Name:

_____________________________ Last Name: __________________________________

Email Address:

__________________________________________________________________________

Job Title:

__________________________________________________________________________

Organization:

__________________________________________________________________________

Address:

__________________________________________________________________________

City:

__________________________________________________________________________

Postal / Zip Code:

__________________________________________________________________________

Country:

__________________________________________________________________________

Phone Number:

__________________________________________________________________________

Fax Number:

__________________________________________________________________________

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

Page 15/16


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________

Expiry Date

__________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

 

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms

Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56

ƒ ƒ

Asia, Oceania and America : + 1 (805) 617 17 93

Global Angiongenesis Inhibitors and Stimulators Industry (From Issuu)

Page 16/16


Global Angiongenesis Inhibitors and Stimulators Industry